{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825895306972800.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1872-034x.2007.00263.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1872-034X.2007.00263.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1872-034X.2007.00263.x"}},{"identifier":{"@type":"PMID","@value":"17877726"}}],"dc:title":[{"@value":"Prevalence of hepatitis B virus infection in Japanese patients with HIV"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>Patients with HIV infection are frequently infected with hepatitis viruses, which are presently the major cause of mortality in HIV‐infected patients after the widespread use of highly active antiretrovirus therapy. We previously reported that approximately 20% of HIV‐positive Japanese patients were also infected with hepatitis C virus (HCV). Hepatitis B virus (HBV) infection may also be an impediment to a good course of treatment for HIV‐infected patients, because of recurrent liver injuries and a common effectiveness of some anti‐HIV drugs on HBV replication. However, the status of co‐infection with HIV and HBV in Japan is unclear. We conducted a nationwide survey to determine the prevalence of HIV–HBV co‐infection by distributing a questionnaire to the hospitals belonging to the HIV/AIDS Network of Japan. Among the 5998patients reported to be HIV positive, 377 (6.4%) were positive for the hepatitis B surface antigen. Homosexual men accounted for two‐thirds (70.8%) of the HIV–HBV co‐infected patients, distinct from HIV–HCV co‐infection in Japan in which most of the HIV–HCV co‐infected patients were recipients of blood products. One‐third of HIV–HBV co‐infected patients had elevated serum alanine aminotransferase levels at least once during the 1‐year observation period. In conclusion, some HIV‐infected Japanese patients also have HBV infection and liver disease. A detailed analysis of the progression and activity of liver disease in co‐infected patients is needed.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825895306972932","@type":"Researcher","foaf:name":[{"@value":"Kazuhiko Koike"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895306972928","@type":"Researcher","foaf:name":[{"@value":"Yoshimi Kikuchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895306972803","@type":"Researcher","foaf:name":[{"@value":"Michio Kato"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895306972933","@type":"Researcher","foaf:name":[{"@value":"Junki Takamatsu"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895306972800","@type":"Researcher","foaf:name":[{"@value":"Yoshizumi Shintani"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895306972801","@type":"Researcher","foaf:name":[{"@value":"Takeya Tsutsumi"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895306972931","@type":"Researcher","foaf:name":[{"@value":"Hajime Fujie"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895306972930","@type":"Researcher","foaf:name":[{"@value":"Hideyuki Miyoshi"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895306972929","@type":"Researcher","foaf:name":[{"@value":"Kyoji Moriya"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895306972802","@type":"Researcher","foaf:name":[{"@value":"Hiroshi Yotsuyanagi"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13866346"},{"@type":"EISSN","@value":"1872034X"}],"prism:publicationName":[{"@value":"Hepatology Research"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2007-09-17","prism:volume":"38","prism:number":"3","prism:startingPage":"310","prism:endingPage":"314"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1872-034X.2007.00263.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1872-034X.2007.00263.x"}],"createdAt":"2007-09-20","modifiedAt":"2023-10-11","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004235523991168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Detection of highly prevalent hepatitis <scp>B</scp> virus co‐infection with <scp>HIV</scp> in <scp>I</scp>ndonesia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004236848630144","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Human immunodeficiency virus and hepatitis B genotype G/A2 recombinant co-infection: a case study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567183036660352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevalence and epidemiological traits of HIV infections in populations with high-risk behaviours as revealed by genetic analysis of HBV"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848657213536896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792912128","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Universal hepatitis B vaccination: pros and cons"},{"@language":"ja","@value":"ユニバーサルＨＢワクチネーション：是か非か？"},{"@language":"ja-Kana","@value":"ユニバーサル HB ワクチネーション ゼ カ ヒ カ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204794520320","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Transition and problems of hepatitis B virus genotypes among patients with acute and chronic infection in Japan"},{"@language":"ja","@value":"わが国におけるB型肝炎ウィルス遺伝子型の変遷と問題点"},{"@value":"Editorial わが国におけるB型肝炎ウィルス遺伝子型の変遷と問題点"},{"@language":"ja-Kana","@value":"Editorial ワガクニ ニ オケル Bガタ カンエン ウィルス イデンシガタ ノ ヘンセン ト モンダイテン"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205011409920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"HIV/AIDS感染症の現状と展望"},{"@value":"他領域からのトピックス HIV/AIDS感染症の現状と展望"},{"@language":"ja-Kana","@value":"タ リョウイキ カラ ノ トピックス HIV/AIDS カンセンショウ ノ ゲンジョウ ト テンボウ"},{"@language":"en","@value":"[Current status and overview of HIV/AIDS infection]."}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205048571520","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A Case of Hepatitis B Virus/human Immunodeficiency Virus Coinfection in a Patient Who Achived Hepatitis B Surface Antigen Seroclearance After Interferon Therapy Followed by Antiretroviral Therapy without Developing Immune Reconstitution Inflammatory Syndrome"},{"@language":"ja","@value":"インターフェロン先行投与後の抗レトロウイルス療法により免疫再構築症候群の発症なくHBs 抗原の陰性化が得られた HBV/HIV 重複感染の1 例"},{"@value":"症例 インターフェロン先行投与後の抗レトロウイルス療法により免疫再構築症候群の発症なくHBs抗原の陰性化か得られたHBV/HIV重複感染の1例"},{"@language":"ja-Kana","@value":"ショウレイ インターフェロン センコウ トウヨ ゴ ノ コウレトロウイルス リョウホウ ニ ヨリ メンエキ サイコウチク ショウコウグン ノ ハッショウ ナク HBs コウゲン ノ インセイカ カ エラレタ HBV/HIV チョウフク カンセン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771660672","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Universal vaccination of hepatitis B virus vaccine"},{"@language":"ja","@value":"B型肝炎universal vaccinationへ向けて"},{"@language":"ja-Kana","@value":"Bガタ カンエン universal vaccination エ ムケテ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679847533440","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"An HIV Patient with Hepatic Flare after the Initiation of HBV-active Antiretroviral Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679850323712","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B Virus-related Immune Reconstitution Inflammatory Syndrome in Two Patients Coinfected with Human Immunodeficiency Virus Diagnosed with a Liver Biopsy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2007.00263.x"},{"@type":"OPENAIRE","@value":"doi_dedup___::ae92031f5516bc95ca89c9fde5858277"},{"@type":"CROSSREF","@value":"10.1111/hepr.12053_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.1186/s40064-016-3169-2_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.1016/j.jiac.2014.12.003_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.3950/jibiinkoka.115.759_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.51.7244_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.1017/s0950268812003123_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.2957/kanzo.49.549_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.117_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.2957/kanzo.50.598_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.11150/kansenshogakuzasshi.86.763_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.53.2503_references_DOI_70Ku7AyDzJFm49r4fKWdUFFhOFB"}]}